her3 extracellular domain (Sino Biological)

Sino Biological her3 extracellular domain

Representative images and quantifications of IHC staining of <t>phospho-HER3</t> (P-HER3) at Y1289 using human tissues form normal mucosa, primary CRC, mCRC lymph node metastases, and mCRC liver metastases. Sections were counter stained with hematoxylin. Scale bars 100 µm. Mean +/-SD, *p<0.05 by one-way ANOVA test.

Her3 Extracellular Domain, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/her3 extracellular domain/product/Sino Biological
Average 94 stars, based on 1 article reviews

her3 extracellular domain - by Bioz Stars, 2026-03

94/100 stars

Buy from Supplier

her3 extracellular domain (ecd (R&D Systems)

R&D Systems her3 extracellular domain (ecd

Her3 Extracellular Domain (Ecd, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/her3 extracellular domain (ecd/product/R&D Systems
Average 90 stars, based on 1 article reviews

her3 extracellular domain (ecd - by Bioz Stars, 2026-03

90/100 stars

Buy from Supplier

minidawn (Waters Corporation)

Waters Corporation minidawn

Minidawn, supplied by Waters Corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/minidawn/product/Waters Corporation
Average 94 stars, based on 1 article reviews

minidawn - by Bioz Stars, 2026-03

94/100 stars

Buy from Supplier

Image Search Results

Representative images and quantifications of IHC staining of phospho-HER3 (P-HER3) at Y1289 using human tissues form normal mucosa, primary CRC, mCRC lymph node metastases, and mCRC liver metastases. Sections were counter stained with hematoxylin. Scale bars 100 µm. Mean +/-SD, *p<0.05 by one-way ANOVA test.

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: Representative images and quantifications of IHC staining of phospho-HER3 (P-HER3) at Y1289 using human tissues form normal mucosa, primary CRC, mCRC lymph node metastases, and mCRC liver metastases. Sections were counter stained with hematoxylin. Scale bars 100 µm. Mean +/-SD, *p<0.05 by one-way ANOVA test.

Article Snippet: Recombinant human LRG1 (Cat# 13371-HCCH), HER3 extracellular domain (HER3-ECD, Cat# 10201-H08H) and HER2 extracellular domain (HER2-ECD, Cat# 10004-H08H) were from Sinobiological (Houston, TX).

Techniques: Immunohistochemistry, Staining

(A) The MTT assay showed CRC cell viability after 72 hours incubation in CM from CRC cells or different liver EC lines. Mean +/-SEM, ***p<0.001, **p<0.01 by unpaired two-tailed t -test. (B) Western blotting showed NRG1 in CM from EC-9 cells with either control or NRG1-specific siRNAs, and P-HER3 levels in CRC cells after 30 minutes treating with CRC CM, or CM from EC-9 with control or NRG1-specific siRNAs.

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: (A) The MTT assay showed CRC cell viability after 72 hours incubation in CM from CRC cells or different liver EC lines. Mean +/-SEM, ***p<0.001, **p<0.01 by unpaired two-tailed t -test. (B) Western blotting showed NRG1 in CM from EC-9 cells with either control or NRG1-specific siRNAs, and P-HER3 levels in CRC cells after 30 minutes treating with CRC CM, or CM from EC-9 with control or NRG1-specific siRNAs.

Techniques: MTT Assay, Incubation, Two Tailed Test, Western Blot

$(A) Schematics of CM fractionation by FPLC. (B) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with EC-9 CM fractions. (C) Schematics of HER3-ECD with His tags pulling down soluble factors from EC-9 CM. Green, HER3-ECD. Red, EC-secreted factor(s) that bind to HER3-ECD. (D) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with EC-9 CM after beads or ECD depletion, or with soluble factors eluted from beads or ECD. Ctrl beads: Ni-NAT beads only without ECD. Ctrl ECD: HER2-ECD. (E) The MTT assay showed CRC cell viability after 72 hours incubating with CM. (F) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with LRG1 peptides. (G) The MTT assay showed CRC cell viability after 72 hours treating with CM or LRG1 (250 ng/ml). (H) Western blotting showed soluble LRG1 in CM from EC-1 and -9 cells. (I) Western blotting showed LRG1 pulled down by HER3-ECD. (J) SPR assay determined LRG1 and HER3-ECD binding affinity. K D =K on /K off , 1:1 fit model. In (E) and (G), data are shown as Mean +/-SEM, ***p<0.001, **p<0.01, *p<0.05 by unpaired two-tailed t -test.$

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: (A) Schematics of CM fractionation by FPLC. (B) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with EC-9 CM fractions. (C) Schematics of HER3-ECD with His tags pulling down soluble factors from EC-9 CM. Green, HER3-ECD. Red, EC-secreted factor(s) that bind to HER3-ECD. (D) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with EC-9 CM after beads or ECD depletion, or with soluble factors eluted from beads or ECD. Ctrl beads: Ni-NAT beads only without ECD. Ctrl ECD: HER2-ECD. (E) The MTT assay showed CRC cell viability after 72 hours incubating with CM. (F) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with LRG1 peptides. (G) The MTT assay showed CRC cell viability after 72 hours treating with CM or LRG1 (250 ng/ml). (H) Western blotting showed soluble LRG1 in CM from EC-1 and -9 cells. (I) Western blotting showed LRG1 pulled down by HER3-ECD. (J) SPR assay determined LRG1 and HER3-ECD binding affinity. K D =K on /K off , 1:1 fit model. In (E) and (G), data are shown as Mean +/-SEM, ***p<0.001, **p<0.01, *p<0.05 by unpaired two-tailed t -test.

Techniques: Fractionation, Western Blot, MTT Assay, SPR Assay, Binding Assay, Two Tailed Test

(A) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with EC-1 CM with or without beads or ECD depletion, or with soluble factors eluted from beads or ECD. (B) Western blotting showed P-HER3 and P-SMAD3 levels in CRC cells with functional TGFβ receptors after 30 minutes treating with LRG1 or TGFβ peptides.

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: (A) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with EC-1 CM with or without beads or ECD depletion, or with soluble factors eluted from beads or ECD. (B) Western blotting showed P-HER3 and P-SMAD3 levels in CRC cells with functional TGFβ receptors after 30 minutes treating with LRG1 or TGFβ peptides.

Techniques: Western Blot, Functional Assay

(A) Western blotting showed LRG1 levels in CM from ECs with control or LRG1-specific siRNAs. (B) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with CM from CRC, or from EC-9 with control or LRG1-specific siRNAs. (C) The MTT assay showed CRC cell viability after 72 hours incubating with CM. (D) Western blotting showed LRG1 levels on pull-down beads with control or LRG1 antibodies, or in EC-9 CM after immuno-depletion by control or LRG1 antibodies. (E) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with CRC CM or EC-9 CM after immuno-depletion by control or LRG1 antibodies. (F) The MTT assay showed CRC cell viability after 72 hours incubating with CM. (G) Tumor volumes of subQ xenografts treated by CRC CM, complete EC-9 CM, or LRG1-depleted EC-9 CM (n=8 mice/group). For (C) and (F), data are shown as Mean +/-SEM, **p<0.01, *p<0.05 by unpaired two-tailed t -test. For (G), data are Mean -/+ SD, **p<0.01, *p<0.05 by Wilcoxon rank-sum test.

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: (A) Western blotting showed LRG1 levels in CM from ECs with control or LRG1-specific siRNAs. (B) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with CM from CRC, or from EC-9 with control or LRG1-specific siRNAs. (C) The MTT assay showed CRC cell viability after 72 hours incubating with CM. (D) Western blotting showed LRG1 levels on pull-down beads with control or LRG1 antibodies, or in EC-9 CM after immuno-depletion by control or LRG1 antibodies. (E) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with CRC CM or EC-9 CM after immuno-depletion by control or LRG1 antibodies. (F) The MTT assay showed CRC cell viability after 72 hours incubating with CM. (G) Tumor volumes of subQ xenografts treated by CRC CM, complete EC-9 CM, or LRG1-depleted EC-9 CM (n=8 mice/group). For (C) and (F), data are shown as Mean +/-SEM, **p<0.01, *p<0.05 by unpaired two-tailed t -test. For (G), data are Mean -/+ SD, **p<0.01, *p<0.05 by Wilcoxon rank-sum test.

Techniques: Western Blot, MTT Assay, Two Tailed Test

(A) Kaplan-Meier curve for overall survival of mice with MC-38 mCRC allografts in the liver of WT mice and LRG1 KO mice (n=5 mice/group). (B) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with CM and the LRG1 neutralizing antibody 15C4. (C) The MTT assay showed CRC cell viability after 72 hours incubating with CM and 15C4. (D) HCP-1 subQ xenograft mean volume over time, and images and weights of harvested subQ xenograft from mice treated with CM and 15C4 (n=10 mice/group). (E) Representative images of P-HER3 (Y1289) IHC staining of HCP-1 xenografts. For (A) and (D), data are Mean -/+ SD, **p<0.01, *p<0.05 by Wilcoxon rank-sum test. For (C), data are shown as Mean +/-SEM, ***p<0.001, **p<0.01, *p<0.05 by unpaired two-tailed t -test.

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: (A) Kaplan-Meier curve for overall survival of mice with MC-38 mCRC allografts in the liver of WT mice and LRG1 KO mice (n=5 mice/group). (B) Western blotting showed P-HER3 levels in CRC cells after 30 minutes treating with CM and the LRG1 neutralizing antibody 15C4. (C) The MTT assay showed CRC cell viability after 72 hours incubating with CM and 15C4. (D) HCP-1 subQ xenograft mean volume over time, and images and weights of harvested subQ xenograft from mice treated with CM and 15C4 (n=10 mice/group). (E) Representative images of P-HER3 (Y1289) IHC staining of HCP-1 xenografts. For (A) and (D), data are Mean -/+ SD, **p<0.01, *p<0.05 by Wilcoxon rank-sum test. For (C), data are shown as Mean +/-SEM, ***p<0.001, **p<0.01, *p<0.05 by unpaired two-tailed t -test.

Techniques: Western Blot, MTT Assay, Immunohistochemistry, Two Tailed Test

(A, B) Principal component analysis and volcano plot were used for clustering of identified serine- and threonine-protein phosphorylation in CRC cells after 30 minutes culturing in CRC or EC-9 CM. (C) Western blotting showed P-eIF4B levels in CRC cells with or without siRNA of HER3 and after 30 minutes treating with or without LRG1. (D) Western blotting showed P-eIF4B levels in CRC cells after 30 minutes treating with CM and with or without the LRG1 neutralizing antibody 15C4. (E) The global protein synthesis assay showed the levels of de novo protein synthesis in CRC cells after 24 hours incubation with CM and 15C4. (F) The MTT assay showed CRC cell viability after 72 hours incubating with CM and an eIF4 inhibitor. (G) Representative images and quantifications of P-eIF4 IHC staining of HCP-1 xenografts treated by CM from CRC or EC-9, and with/without 15C4. For (E) and (F), data are shown as Mean +/-SEM, ***p<0.001, **p<0.01, *p<0.05.

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: (A, B) Principal component analysis and volcano plot were used for clustering of identified serine- and threonine-protein phosphorylation in CRC cells after 30 minutes culturing in CRC or EC-9 CM. (C) Western blotting showed P-eIF4B levels in CRC cells with or without siRNA of HER3 and after 30 minutes treating with or without LRG1. (D) Western blotting showed P-eIF4B levels in CRC cells after 30 minutes treating with CM and with or without the LRG1 neutralizing antibody 15C4. (E) The global protein synthesis assay showed the levels of de novo protein synthesis in CRC cells after 24 hours incubation with CM and 15C4. (F) The MTT assay showed CRC cell viability after 72 hours incubating with CM and an eIF4 inhibitor. (G) Representative images and quantifications of P-eIF4 IHC staining of HCP-1 xenografts treated by CM from CRC or EC-9, and with/without 15C4. For (E) and (F), data are shown as Mean +/-SEM, ***p<0.001, **p<0.01, *p<0.05.

Techniques: Western Blot, Incubation, MTT Assay, Immunohistochemistry

(A) Western blotting showed P-HER3, P-eIF4B, and P-AKT levels in CRC cells after 30 minutes treating with either LRG1 or neuregulins (NRGs). (B) Western blotting showed P-eIF4B levels in CRC cells after 30 minutes treating with LRG1 and different doses of AKT inhibitors (MK-2206). (C) Western blotting showed P-eIF4B levels in CRC cells after 30 minutes treating with LRG1 and different doses of IRS inhibitors (NT157), p110α inhibitors (BYL719), PDK1 inhibitors (BX795), and RSK inhibitors (BI-D1870). (D) The global protein synthesis assay showed the levels of de novo protein synthesis in CRC cells after 24 hours incubation with LRG1 and specific inhibitors. (E) Schematics of the signaling pathway. For (D), data are shown as Mean +/-SEM, **p<0.01, by unpaired two-tailed t -test.

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: (A) Western blotting showed P-HER3, P-eIF4B, and P-AKT levels in CRC cells after 30 minutes treating with either LRG1 or neuregulins (NRGs). (B) Western blotting showed P-eIF4B levels in CRC cells after 30 minutes treating with LRG1 and different doses of AKT inhibitors (MK-2206). (C) Western blotting showed P-eIF4B levels in CRC cells after 30 minutes treating with LRG1 and different doses of IRS inhibitors (NT157), p110α inhibitors (BYL719), PDK1 inhibitors (BX795), and RSK inhibitors (BI-D1870). (D) The global protein synthesis assay showed the levels of de novo protein synthesis in CRC cells after 24 hours incubation with LRG1 and specific inhibitors. (E) Schematics of the signaling pathway. For (D), data are shown as Mean +/-SEM, **p<0.01, by unpaired two-tailed t -test.

Techniques: Western Blot, Incubation, Two Tailed Test

(A) Western blotting showed P-eIF4B levels in HCT116 cells after 30 minutes treating with LRG1 and different doses of IRS inhibitors (NT157), p110α inhibitors (BYL719), PDK1 inhibitors (BX795), and RSK inhibitors (BI-D1870). (B) Western blotting showed P-HER3 and P-eIF4B levels in CRC cells after 30 minutes treating with LRG1 and different doses of p110β inhibitors (TGX-221). (C) The global protein synthesis assay showed the levels of de novo protein synthesis in CRC cells after 24 hours incubation with LRG1 and p110β inhibitors, mean +/-SEM, **p<0.01, by unpaired two-tailed t -test.

Journal: bioRxiv

Article Title: LRG1 is a novel ligand of HER3 and promotes metastatic colorectal cancer growth

doi: 10.1101/2023.02.18.529070

Figure Lengend Snippet: (A) Western blotting showed P-eIF4B levels in HCT116 cells after 30 minutes treating with LRG1 and different doses of IRS inhibitors (NT157), p110α inhibitors (BYL719), PDK1 inhibitors (BX795), and RSK inhibitors (BI-D1870). (B) Western blotting showed P-HER3 and P-eIF4B levels in CRC cells after 30 minutes treating with LRG1 and different doses of p110β inhibitors (TGX-221). (C) The global protein synthesis assay showed the levels of de novo protein synthesis in CRC cells after 24 hours incubation with LRG1 and p110β inhibitors, mean +/-SEM, **p<0.01, by unpaired two-tailed t -test.

Techniques: Western Blot, Incubation, Two Tailed Test

her3 extracellular domain (ecd Search Results

Image Search Results